Champions Oncology, Inc.
CSBR
$5.96
$0.111.88%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.10% | 9.06% | 10.11% | 13.54% | 19.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.10% | 9.06% | 10.11% | 13.54% | 19.03% |
| Cost of Revenue | 10.56% | -1.53% | 1.81% | -3.45% | -3.80% |
| Gross Profit | -12.05% | 22.14% | 20.56% | 37.59% | 53.15% |
| SG&A Expenses | 19.80% | 8.80% | -3.37% | -6.87% | -8.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.00% | 3.78% | -1.51% | -8.72% | -10.61% |
| Operating Income | -133.06% | 799.72% | 199.05% | 170.03% | 176.43% |
| Income Before Tax | -137.46% | 470.60% | 182.71% | 163.32% | 166.28% |
| Income Tax Expenses | -111.54% | -94.74% | -113.16% | -138.71% | -137.14% |
| Earnings from Continuing Operations | -136.46% | 506.52% | 186.02% | 164.61% | 166.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -135.51% | 516.72% | 186.90% | 164.61% | 166.07% |
| EBIT | -133.06% | 799.72% | 199.05% | 170.03% | 176.43% |
| EBITDA | -109.17% | 176.85% | 490.33% | 228.36% | 221.01% |
| EPS Basic | -135.23% | 515.72% | 186.37% | 164.17% | 165.46% |
| Normalized Basic EPS | -127.57% | 1,476.09% | 205.92% | 171.07% | 176.55% |
| EPS Diluted | -137.68% | 372.64% | 173.95% | 158.23% | 160.46% |
| Normalized Diluted EPS | -128.90% | 1,062.81% | 197.01% | 167.16% | 173.51% |
| Average Basic Shares Outstanding | 1.36% | 1.21% | 1.03% | 0.83% | 0.60% |
| Average Diluted Shares Outstanding | -0.23% | 2.02% | 2.19% | 3.67% | 3.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |